INTERNATIONAL SEARCH REPORT

International application No. PCT/JP2004/005152

CLASSIFICATION OF SUBJECT MATTER
Int.Cl⁷ C12N15/09, C07K16/28, C07K16/46, A61P35/00, A61P37/02, A61P43/00, A61K39/395

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

天智由所所自由

4ララーロボックカのある

Minimum documentation searched (classification system followed by classification symbols) C12N15/09, C07K16/28, C07K16/46, A61P35/00, A61P37/02, A61P43/00, A61K39/395

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) MEDLINE, BIOSIS/WPI(DIALOG), SwissProt/PIR/GeneSeq, Genbank/EMBL/DDBJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Hudson P.J. et al., High avidity scFv multimers; diabodies and triabodies, J.Immunol.Methods, 1999, Vol.231, pages 177 to 189	1-14
Y	Kortt A.A. et al., Dimeric and trimeric anti bodies: high avidity scFvs for cancer target ing, Biomol.Eng., 2001, Vol.18, pages 95 to 108	1-14
Y	Xiong D. et al., Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20 x anti-CD3 bispecific diabody, Cancer Lett., 2002, Vol.177, pages 29 to 39	1-14

×	Further documents are listed in the continuation of Box C.		See patent family annex.
* "A"	Special categories of cited documents: document defining the general state of the art which is not considered	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand
А	to be of particular relevance		the principle or theory underlying the invention
"E"	earlier application or patent but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other		"Y"	document of particular relevance; the claimed invention cannot be
"O"	special reason (as specified)	•	considered to involve an inventive step when the document is combined with one or more other such documents, such combination
"P"	document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than	"&"	being obvious to a person skilled in the art
_	the priority date claimed		document member of the same patent family
	of the actual completion of the international search	Date	of mailing of the international search report
	05 July, 2004 (05.07.04)	i	20 July, 2004 (20.07.04)
	e and mailing address of the ISA/	Auth	orized officer
	Japanese Patent Office	l	

Telephone No.

Form PCT/ISA/210 (second sheet) (January 2004)

Facsimile No.

三日 まりかられているちゃ

INTERNATIONAL SEARCH REPORT

International application No.
PCT/JP2004/005152

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Y	MATSUOKA S. et al., A novel type of cell death of lymphocytes induced by a monoclonal antibody without participation of complement, J.Exp.Med., 1995, Vol.181, pages 2007 to 2015	1-14
Y	Fayen J. et al., Negative signaling by anti- HLA class I antibodies is dependent upon two triggering events, Int.Immunol., 1998, Vol.10, pages 1347 to 1358	1-14
Y	Woodle E.S. et al., Anti-human class I MHC antibodies induce apoptosis by a pathway that is distinct from the Fas antigen-mediated path way, J.Immunol., 1997, Vol.158, pages 2156 to 2164	1-14
Y	Tahtis k. et al., Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2), constructs in a breast carcinoma xenograft model, Clin.Cancer Res., 2001, Vol.7, pages 1061 to 1072	1-14
Y	Rossi E.A. et al., Development of new multi valent-bispecific agents for pretargeting tumor localization and therapy, Clin.Cancer Res., 2003, Vol.9, pages 3886S to 3896S	1-14
E,X	WO 04/033499 A1 (Chugai Pharmaceutical Co., Ltd.), 22 April, 2004 (22.04.04), Full text (Family: none)	1-14